Warter J M, Marescaux C, Brandt C, Rumbach L, Micheletti G, Chabrier G, Imler M, Kurtz D
Epilepsia. 1983 Oct;24(5):628-33. doi: 10.1111/j.1528-1157.1983.tb03428.x.
Treatment with sodium valproate (VPA) in association with phenobarbital (PB) is accompanied by a greater systemic hyperammonemia than treatment by VPA alone. The anatomical origins of this difference were studied by injecting a dose of 1,500 mg VPA i.v. into six unmedicated patients and six epileptics chronically treated with PB and measuring the ammonium (NH4+) concentration difference between arterial blood and renal, hepatic, internal jugular, and femoral venous blood. In unmedicated patients, arterial [NH4+] rose moderately, secondary to an increased amount of NH4+ released into the general circulation by the kidney; the hepatic metabolism of NH4+ remained normal. In epileptics treated with PB, arterial [NH4+] rose massively, partly as a result of the increased NH4+ release by the kidney and partly because of disturbance of the hepatic metabolism of NH4+. These results provide a clearer understanding of the potentiation of the secondary effects of VPA by PB.
与单独使用丙戊酸钠(VPA)治疗相比,丙戊酸钠(VPA)联合苯巴比妥(PB)治疗会伴随更严重的全身性高氨血症。通过对6名未接受药物治疗的患者和6名长期接受PB治疗的癫痫患者静脉注射1500mg VPA,并测量动脉血与肾、肝、颈内静脉和股静脉血之间的铵(NH4+)浓度差异,研究了这种差异的解剖学起源。在未接受药物治疗的患者中,由于肾脏释放到全身循环中的NH4+量增加,动脉[NH4+]适度升高;NH4+的肝脏代谢保持正常。在接受PB治疗的癫痫患者中,动脉[NH4+]大幅升高,部分原因是肾脏释放的NH4+增加,部分原因是NH4+的肝脏代谢受到干扰。这些结果为PB增强VPA的继发效应提供了更清晰的理解。